IDEXX Laboratories, Inc. $IDXX Stake Lowered by HBW Advisory Services LLC

HBW Advisory Services LLC trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,153 shares of the company’s stock after selling 114 shares during the quarter. HBW Advisory Services LLC’s holdings in IDEXX Laboratories were worth $1,155,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of IDXX. MorganRosel Wealth Management LLC acquired a new stake in IDEXX Laboratories during the first quarter worth about $26,000. Migdal Insurance & Financial Holdings Ltd. raised its holdings in IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after acquiring an additional 30 shares during the period. WPG Advisers LLC bought a new position in shares of IDEXX Laboratories during the first quarter worth approximately $37,000. Bank of Jackson Hole Trust boosted its position in IDEXX Laboratories by 328.6% in the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock valued at $39,000 after buying an additional 69 shares in the last quarter. Finally, Retirement Wealth Solutions LLC raised its stake in IDEXX Laboratories by 40.0% during the first quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company’s stock worth $44,000 after buying an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other news, EVP Sharon E. Underberg sold 5,450 shares of the stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the transaction, the executive vice president owned 6,156 shares of the company’s stock, valued at approximately $4,011,249.60. This represents a 46.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Nimrata Hunt sold 7,143 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total value of $4,503,161.49. Following the sale, the executive vice president owned 18,007 shares of the company’s stock, valued at approximately $11,352,153.01. The trade was a 28.40% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 54,057 shares of company stock valued at $34,293,468. Corporate insiders own 0.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IDXX. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price target on the stock. BTIG Research boosted their price objective on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. JPMorgan Chase & Co. increased their price objective on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, August 4th. Morgan Stanley raised their price objective on IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a report on Friday, August 15th. Finally, Stifel Nicolaus set a $640.00 price target on IDEXX Laboratories in a report on Monday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $649.44.

IDEXX Laboratories Trading Down 0.6%

Shares of NASDAQ IDXX opened at $641.14 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $688.12. The stock’s 50 day simple moving average is $603.59 and its 200 day simple moving average is $513.68. The company has a market cap of $51.29 billion, a price-to-earnings ratio of 53.38, a price-to-earnings-growth ratio of 4.18 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.